Carvedilol Tablet, Film Coated
Product Images NDC 51655-033

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Carvedilol (NDC 51655-033). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

51655 033 25 Master Bottle Label Approval Rev A 01 22

51655 033 25 Master Bottle Label Approval Rev A 01 22
Label for Carvedilol Tablets USP 25 mg, containing 60 film-coated tablets. The label indicates prescription use only and provides storage instructions to keep the product at controlled room temperature (20°-25°C). Packaged by Northwind Pharmaceuticals Inc., USA, the label includes a barcode, QR code, and batch/lot information placeholders.*
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
A line graph showing percentage mortality over 21 months comparing Carvedilol and placebo groups. The x-axis represents months, and the y-axis represents % mortality, with Carvedilol consistently showing lower mortality than placebo. A p-value of 0.0014 is indicated, suggesting statistical significance.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A forest plot displaying hazard ratios with confidence intervals across various patient subgroups including gender (Men, Women), age (<65, 65), race (Non-black, Black), diabetic status (Diabetic, Non-diabetic), ischemic condition (Ischemic, Nonischemic), heart rate categories (7, <70), systolic blood pressure (SBP 120 mm Hg, <120 mm Hg), spironolactone use (Yes, No), and all patients. The horizontal axis represents hazard ratio values from 0 to 2.0 with a vertical reference line at 1.0.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
A survival analysis line graph for the CAPRICORN study showing % mortality over 24 months comparing Carvedilol and placebo groups. The x-axis represents time in months, and the y-axis shows the percentage mortality. The Carvedilol group shows lower mortality than placebo, with a p-value of 0.03 indicating statistical comparison.*
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
A forest plot titled 'Figure 4. Effects on Mortality for Subgroups in CAPRICORN' showing hazard ratios stratified by patient subgroups including age, sex, timing of randomization post myocardial infarction, prior beta-blocker use, Killip class, thrombolytic therapy, PTCA, heart failure history, diuretic use, angina, hypertension, diabetes, heart rate, and systolic blood pressure. The plot displays hazard ratio points with confidence intervals for each subgroup on a horizontal axis from 0.4 to 1.3.*
FDA Label Image

Carvedilol-chemical-structure (Structure)

Carvedilol-chemical-structure (Structure)
Chemical structure diagram of Carvedilol, illustrating the molecular arrangement of atoms and bonds characteristic to the active ingredient Carvedilol.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.